Navigation Links
Rethinking Alzheimer's disease and its treatment targets
Date:9/22/2009

The standard explanation for what causes Alzheimer's is known as the amyloid hypothesis, which posits that the disease results from of an accumulation of the peptide amyloid beta, the toxic protein fragments that deposit in the brain and become the sticky plaques that have defined Alzheimer's for more than 100 years.

Billions of dollars are spent yearly targeting this toxic peptide but what if this is the wrong target? What if the disease begins much earlier, fueled by a natural process? Reporting in the current edition of the journal Neurobiology of Aging, UCLA professor of psychiatry George Bartzokis argues just that and says that a better working hypothesis is the "myelin model."

"The greatest promise of the myelin model of the human brain is its application to the development of new therapeutic approaches," Bartzokis said.

Like insulation around wires, myelin is a fatty sheath that coats our nerve axons, allowing for efficient conduction of nerve impulses. It is key to the fast processing speeds that underlie our higher cognitive functions and encoding of memories.

But the lifelong, extensive myelination of the human brain also makes it uniquely vulnerable to damage. The myelin model's central premise is that it is the normal, routine maintenance and repair of myelin throughout life that ultimately initiates the mechanisms that produce degenerative diseases like Alzheimer's. That is, the amyloid-beta peptide and the tau peptide, which is also implicated in Alzheimer's, as well as the signature clinical signs of the disease, such as memory loss and, ultimately, dementia, are all byproducts of the myelin breakdown and repair processes.

"The pervasive myelination of our brain is the single most unique aspect in which the human brain differs from other species," said Bartzokis, who is a member of the Laboratory of Neuro Imaging in the UCLA Department of Neurology and a member of UCLA's Brain Re
'/>"/>

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Rethinking the genetic theory of inheritance
2. Rethinking who should be considered essential during a pandemic flu outbreak
3. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
4. Paradigm shift in Alzheimerss research: new treatments
5. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
6. Insufficient levels of vitamin D puts elderly at increased risk of dying from heart disease
7. Can an over-the-counter vitamin-like substance slow the progression of Parkinsons disease?
8. UH Manoa researcher examines possible implications of daily commute and mosquito-borne diseases
9. Rare genetic disease successfully reversed using stem cell transplantation
10. Mechanism related to the onset of various genetic diseases revealed
11. NIH funds grantees focusing on epigenomics of human health and disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... macrophages, immune cells that can engulf and poison bacteria ... A new study from the University of Illinois disproves ... PLoS ONE , shows that macrophages focus their most ... targets outside the cytoplasm. Macrophages are voracious eaters ...
... research institutes, announced today the launch of three ... in extreme environments. The three selected genomes are ... and emperor penguin, and one altiplano animal: the ... carried out using Next-generation sequencing technologies, which have ...
... and drainage. Blood vessels feeding the tissues bring in ... While much is known about how blood vessels are ... Now though, Norrmn et al. have identified two of ... mouse embryo. The engineers are the transcription ...
Cached Biology News:New study overturns orthodoxy on how macrophages kill bacteria 2New study overturns orthodoxy on how macrophages kill bacteria 3Genome projects launched for three extreme-environment animals 2Genome projects launched for three extreme-environment animals 3
(Date:5/28/2015)... Dallas, TX (PRWEB) May 28, 2015 ... trade association serving and representing the life sciences ... first Board of Directors meeting at The Foundry ... meeting of the organization brought together a broad ... region, and underscored the organization's early successes in ...
(Date:5/28/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: RXII ... innovative therapeutics, primarily in the areas of dermatology and ... of 26 million units at a price to the ... approximately $10.4 million. Each unit consists of (i) one ... right to purchase 0.50 of a share of common ...
(Date:5/28/2015)... May 28, 2015  GenVec, Inc. (Nasdaq: GNVC ... Douglas J. Swirsky , will present a company overview ... a.m. EDT on Thursday, June 4, 2015. ... presentation will be available at the following link:  ... GenVec,s website.  To access, visit www.genvec.com , click ...
(Date:5/28/2015)... Fertility Centers of New England is proud to announce ... a new and expanded role as Medical Director. In ... and quality assurance for the practice. , “We are ... experienced reproductive endocrinologists,” said Fertility Centers of New England ... and compassionate, individualized care have helped set FCNE apart ...
Breaking Biology Technology:BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... Calif., Oct. 17 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... novel anticancer therapeutics, today announced that the,company ... Conference on,Molecular Targets and Cancer Therapeutics. This ... in San Francisco, California. Preliminary data ...
... call Wednesday, October 24, at 1:30 p.m. EDT, ... AVGN ), a biopharmaceutical company developing innovative ... its quarterly,conference call to discuss third quarter results ... (10:30 a.m. PDT). Kenneth Chahine, Chief Executive,Officer, and ...
... Calif. Carbon nanotubes have been employed for a ... and membranes. , While they have proven useful for ... going on at the molecular level. For example, how ... other on the atomic scale" Answering this question could ...
Cached Biology Technology:Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2Researchers measure carbon nanotube interaction 2
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... provides the premium quality siRNAs you need ... can be readily ordered online by providing ... by providing the sense and antisense siRNA ... and Silencer Pre-designed siRNAs, which are already ...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Biology Products: